Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02017990|
Recruitment Status : Completed
First Posted : December 23, 2013
Last Update Posted : March 3, 2014
|Condition or disease|
|Disorder of Transplanted Kidney|
|Study Type :||Observational|
|Actual Enrollment :||2002 participants|
|Official Title:||The Levels of Marine n-3 Polyunsaturated Fatty Acids in Plasma Phospholipids as a Prognostic Marker of Mortality and Graft Loss Endpoints in Renal Transplant Recipients.|
|Study Start Date :||October 1999|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||June 2013|
Renal transplant recipients
No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
- All-cause mortality [ Time Frame: Up to 12 years. ]First patient recruited October 1999 and all remaining patients were censored at August 2012.
- Loss of function in the renal transplant. [ Time Frame: Up to 12 years. ]As for primary endpoint.
- Cause specific mortality rates. [ Time Frame: Up to 12 years. ]As for the primary endpoint. Mortality rates for cardiac, cerebrovascular, infectious disease and malignancies.
- Cause specific graft loss. [ Time Frame: Up to 12 years. ]As for the primary endpoints. Graft loss rates for rejection and recurrence as well as total and death censored graft loss will be registered.
- Rejection rate. [ Time Frame: Up to 12 years. ]As for the primary endpoint.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02017990
|Oslo University Hospital, Rikshospitalet|
|Oslo, * Oslo, Norway, 0027|
|Principal Investigator:||Ivar Eide, MD||Oslo University Hospital|